Tanvex BioPharma, Inc.

Equities

6541

KYG8676P1037

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 18:00:00 2024-06-26 EDT			5-day change	1st Jan Change
44.55 ^TWD	+1.25%		+13.36%	-31.57%

06-19	Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024	CI
06-19	Tanvex BioPharma, Inc. Announces Change of Audit Committee Members	CI

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

June 19, 2024 at 03:39 am

Tanvex BioPharma, Inc. announced the appointment of Val Chen, VP of Finance - Tanvex BioPharma Inc., Director, Operation Management/chief internal auditor as Corporate governance officer. Effective date: July 1, 2024.

Latest news about Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024	06-19	CI
Tanvex BioPharma, Inc. Announces Change of Audit Committee Members	06-19	CI
Tanvex BioPharma, Inc. Announces Change of Remuneration Committee Members	06-19	CI
Tanvex BioPharma, Inc. Announces Board Changes	06-19	CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from Taiwan TAIEX Index	06-13	CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index	05-27	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-12	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer	02-06	CI
Tanvex BioPharma, Inc. Announces the Appointment of Chen, Lin-Cheng as CEO	02-06	CI
Tanvex Biologics Corporation announced that it expects to receive $5 million in funding from Tanvex BioPharma, Inc.	02-05	CI
Tanvex BioPharma USA, Inc. announced that it expects to receive $50 million in funding from Tanvex BioPharma, Inc.	02-05	CI
Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer	01-05	CI
Tanvex BioPharma, Inc. Announces Change of Chairman	12-29	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen Chairperson and Director, Effective December 29, 2023	12-21	CI
Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer	12-21	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as CEO, Effective December 29, 2023	12-21	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as Chairman/President, Effective December 29, 2023	12-21	CI
Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer	11-30	CI
Tanvex BioPharma, Inc. Appoints Wen Chung Yeh as Chief Financial Officer	11-13	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-12	CI
Tanvex BioPharma, Inc. Announces Management Changes	11-01	CI
Tanvex BioPharma, Inc.(TWSE:6541) added to S&P Global BMI Index	23-09-17	CI
Tanvex BioPharma, Inc.(TWSE:6541) added to Taiwan TAIEX Index	23-09-06	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI

Chart Tanvex BioPharma, Inc.

Duration

Period

More charts

Company Profile

Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
TANVEX BIOPHARMA, INC.	-31.57%	221M
VERTEX PHARMACEUTICALS INCORPORATED	+16.60%	122B
REGENERON PHARMACEUTICALS, INC.	+20.11%	115B
ARGENX SE	+21.22%	26.64B
BIONTECH SE	-23.46%	19.91B
GENMAB A/S	-17.47%	16.32B
WUXI APPTEC CO., LTD.	-45.95%	15.52B
BEIGENE, LTD.	-18.63%	15.49B
SAREPTA THERAPEUTICS, INC.	+61.86%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+2.69%	13.67B

Bio Therapeutic Drugs